Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Zaleplon - A review of its use in the treatment of insomnia
Autore:
Dooley, M; Plosker, GL;
Indirizzi:
Adis Int Ltd, Auckland 10, New Zealand Adis Int Ltd Auckland New Zealand10 s Int Ltd, Auckland 10, New Zealand
Titolo Testata:
DRUGS
fascicolo: 2, volume: 60, anno: 2000,
pagine: 413 - 445
SICI:
0012-6667(200008)60:2<413:Z-AROI>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
HYPNOTIC DRUGS; ZOLPIDEM; PLACEBO; BENZODIAZEPINES; TOLERABILITY; CL-284,846; MANAGEMENT; ZOPICLONE; EFFICACY; SINGLE;
Keywords:
zaleplon; insomnia; pharmacodynamics; pharmacokinetics; therapeutic use; tolerability;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
75
Recensione:
Indirizzi per estratti:
Indirizzo: Dooley, M Adis Int Ltd, 41 Centorian Dr,Private Bag 65901, Auckland 10, New Zealand Adis Int Ltd 41 Centorian Dr,Private Bag 65901 Auckland New Zealand 10
Citazione:
M. Dooley e G.L. Plosker, "Zaleplon - A review of its use in the treatment of insomnia", DRUGS, 60(2), 2000, pp. 413-445

Abstract

Zaleplon is a pyrazolopyrimidine hypnotic agent which is indicated for theshort term (2 to 4 weeks) management of insomnia. Zaleplon 5 and 10mg at bedtime (usual recommended doses) significantly reduced sleep latency compared with placebo in clinical trials in nonelderly and elderly patients with insomnia. in general, sleep maintenance (sleep duration and number of awakenings) and sleep quality were not significantly different from placebo with zaleplon 5 and 10 mg/night, Zaleplon 20 mg/night significantly improved sleep latency and duration in nonelderly patients, but effects on number of awakenings were inconsistent and sleep quality generally did not improve. The relative hypnotic efficacy of zaleplon compared with that of triazolam and zolpidem is not yet clearly established. Tolerance to the hypnotic effects of zaleplon generally did not occur during 5 weeks' treatment, or during long term treatment (6 or 12 months) according to a small number of studies presented as abstracts. Zaleplon was well tolerated in clinical trials. The most common event was headache but the incidence was similar to that observed with placebo. Zaleplon 5 and 10mg did not impair psychomotor function or memory even immediately after the dose in studies in volunteers or patients with insomnia. Zaleplon 20mg, however, impaired psychomotor function and memory immediately after the dose but next-day effects were not observed. The psychomotor profileof zaleplon appears to be better than that of comparator agents. Rebound insomnia was not observed after sudden discontinuation of up to 12months' treatment with zaleplon 5 and 10 mg/night and up to 4 weeks' treatment with zaleplon 20 mg/night. in addition, the potential for withdrawal syndrome with zaleplon appears to be low according to limited data,In conclusion, zaleplon 5, 10 and 20mg administered st bedtime, or later if patients have difficulty sleeping, is an effective and well tolerated hypnotic agent. There was no evidence of next-day residual effects with the 5 and 10mg dosages, and the incidence of withdrawal effects with zaleplon 5, 10 and 20mg did not differ significantly to that observed with placebo, In addition, tolerance to the effects of zaleplon is unlikely to develop when administered fur the recommended treatment period. The comparative efficacyand tolerability of zaleplon with other short acting nonbenzodiazepine hypnotics is difficult to establish. However, on the basis of current efficacyevidence and the lower incidence of residual effects with zaleplon 5 and 10mg relative to comparator agents, this drug represents a useful option in the management of patients with insomnia who have difficulties initiating sleep.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 22:26:49